Triftazin-Zdorovye, the tab. on 5 mg No. 50

General characteristics. Structure:

International and chemical names: trifluoperazine; 10-[3-(4-metilpiperazin-1-silt) spent on drink] - a 2-trifluorometilfenotiazina dihydrochloride;
main physical and chemical properties: tablets, coated, from blue till green-blue color. On a surface of tablets the mramornost is allowed;
structure: 1 tablet contains a trifluoperazin of a hydrochloride in terms of трифлуоперазин 5 mg; excipients: refined sugar, potato starch, silicon dioxide colloid (aerosil), magnesium stearate, calcium the carbonate besieged gelatin, indigo carmine, beeswax, a liquid paraffin, talc, glycerin.

Pharmacological properties:

Pharmacodynamics. Trifluoperazin treats group of neuroleptics and is one of the most active antipsychotic means. Antipsychotic effect of drug is combined with a certain stimulating effect. Exerts sedative impact at hallucinatory-dilision and hallucinatory states. Drug possesses also antiemetic and expressed cataleptic action.

Pharmacokinetics. Extent of absorption of a trifluoperazin rather high, linkng with proteins of plasma reaches 95%, the effect of the first passing through a liver, bioavailability – 35% takes place. Time of approach of the maximum concentration – 2–4 h. It is intensively metabolized, metabolites are pharmacological not active.

Indications to use:

Schizophrenia, especially paranoid, simple (with an apato-abulichesky syndrome), nuclear schizophrenia with the expressed hallucinatory paranoid phenomena (with psychopatholike, neurosis-like, hypochiondrial, senestopathetic symptomatology), periodic schizophrenia. Triftazin-Zdorovye apply at other mental diseases which course is followed by crazy symptomatology and hallucinations: alcoholic hallucinations and paranoids, involutional psychoses and neurosises. Drug can be used as an antiemetic.

Route of administration and doses:

Triftazin-Zdorovye accept inside after food.
The single dose for adults in an initiation of treatment makes 5 mg of a trifluoperazin (1 tablet). Then it is gradually increased by 5 mg on reception, to a daily dose of 30-80 mg (in some cases – to 100–120 mg). The daily dose is divided into 2–4 receptions. On reaching effect optimum doses are appointed within 1–3 months, and then slowly reduce up to 5–20 mg a day. The last doses apply further as supporting.
At depressive and hallucinatory and depressive and crazy states drug is used together with antidepressants.
For elderly people treatment there begin with half (or less) doses; increase in a dose is carried out more slowly.
For children at the age of 6–12 years the maximum daily dose – 15 mg (treatment there begin with a dose 1 mg 1–2 times a day). In an initiation of treatment I appoint tablets with a smaller dose of a trifluoperazin.
Treatment by drug has to be strictly individualized depending on the course of a disease. Terms of treatment can make 3–9 months and more, depending on efficiency of therapy.
As an antiemetic of Triftazin-Zdorovye it is appointed the adult in a dose of 5 mg (1 tablet) in days.

Features of use:

With care appoint drug to patients with glaucoma (especially with a closed-angle form), epilepsy, a benign hyperplasia of a prostate.
To patients with pathological changes of a picture of blood, Reynaud's syndrome, at a breast cancer, Parkinson's disease, a peptic ulcer of a stomach and a duodenum, an ischuria, chronic diseases of a respiratory organs drug is appointed only after comparison of risk and advantage of treatment.
In need of use of drug in the period of a lactation feeding груддю needs to be interrupted.
During treatment trifluoperaziny the patient should abstain from control of vehicles and the performance of work requiring special attention, speed of mental and motor reactions and also to exclude alcohol intake. At elderly patients development of irreversible diskinetichesky movements is possible. At emergence of symptoms of late dyskinesia treatment needs to be stopped.
In an initiation of treatment drowsiness, an insignificant lowering of arterial pressure can be observed.

Side effects:

From the central nervous system: often – extrapyramidal frustration (dyskinesia, the akineto-rigid phenomena, an akathisia, hyperkinesias, a tremor, vegetative disturbances); in an initiation of treatment – drowsiness, vision disorders; at long reception – late dyskinesia of facial muscles; seldom – a malignant antipsychotic syndrome. From the alimentary system: in an initiation of treatment – dryness in a mouth, anorexia; seldom – cholestatic jaundice. From system of a hemopoiesis: seldom – a leukopenia, thrombocytopenia, an agranulotsitopeniya, a pancytopenia. From cardiovascular system: in an initiation of treatment – tachycardia, moderately expressed orthostatic hypotension; seldom – disturbances of a heart rhythm, change of the electrocardiogram (lengthening of an interval of QT, smoothing of a tooth of T). Allergic reactions: seldom – skin rash, a small tortoiseshell, a Quincke's disease. From endocrine system: seldom – a galactorrhoea, an amenorrhea.

Interaction with other medicines:

At simultaneous use:
with the drugs oppressing the central nervous system (anesthetics, opioid analgetics, barbiturates, anxiolytics, ethanol and etanolsoderzhashchy drugs), strengthening of a depression of the central nervous system and respiratory depression is possible;
with tricyclic antidepressants, Maprotilinum or monoamine oxidase inhibitors – increase in risk of a malignant antipsychotic syndrome is possible;
with anticonvulsant drugs – decrease in a convulsive threshold is possible;
with drugs for treatment of a hyperthyroidism – the risk of development of an agranulocytosis increases;
with the drugs causing extrapyramidal reactions – increase in frequency and weight of extrapyramidal disturbances is possible;
with anti-hypertensive drugs – orthostatic hypotension is possible;
with prochlorperazine - the long loss of consciousness is possible;
with adrenaline – a perversion of effect of the last that leads to a further lowering of arterial pressure.
Drug can weaken vasoconstrictive effect of ephedrine, strengthen anticholinergic effects of other drugs, suppress effect of amphetamines, levodopas, a clonidine, a guanetidin. Antacids, antiparkinsonichesky means and drugs of lithium break absorption of a trifluoperazin.

Contraindications:

Acute and chronic inflammatory diseases of a liver, heart trouble with disturbance of conductivity and in decompensation stages, a serious illness of kidneys, oppression of a marrowy blood formation, pregnancy, the lactation period, children's age up to 6 years, hypersensitivity to drug.

Overdose:

Symptoms: emergence of signs of a malignant antipsychotic syndrome, first of which can be fervescence. In hard cases disturbance of consciousness up to a coma can be observed. Treatment: dose decline or termination of administration of drug; as proofreaders of extrapyramidal frustration apply antiparkinsonichesky means (Tropacinum, Cyclodolum); are stopped to dyskinesia (paroxysmal myotonia of a neck, language, a bottom of an oral cavity, okulogirny crises) caffeine-sodium benzoate (2 ml of 20% of solution subcutaneously) or aminazine (1–2 ml of 2,5% of solution intramusculary).

Storage conditions:

To store in the dry, protected from light place at a temperature from 15 °C to 25 °C. To store in the place, unavailable to children.
Period of validity – 2 years.

Issue conditions:

According to the recipe

Packaging:

Tablets, coated, on 5 mg No. 10х5, No. 50 in blister strip packagings.